Caroline Seymour
Articles
RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple Myeloma
June 08, 2022
Article
Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.
Addition of Sorafenib to Chemotherapy Found to be Safe, Effective in Pediatric FLT3-ITD+ AML
June 01, 2022
Article
Standard chemotherapy plus sorafenib achieved clinical benefit in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.
Nivolumab/Ipilimumab Elicits Promising PFS in Second-Line Metastatic Melanoma
April 17, 2022
Article
An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.
Adding Atezolizumab to Chemoradiation Promotes T-Cell Clonal Expansion in Node-Positive Cervical Cancer
March 26, 2022
Article
Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.
NCCN Clinical Practice Guidelines Now Include Duvelisib for Peripheral T-cell Lymphoma
March 17, 2022
Article
Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.
Niraparib/Abiraterone Combo Linked to Improved rPFS in Select Patients With mCRPC
February 18, 2022
Article
A frontline regimen of niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with homologous recombination repair gene altered–metastatic castration-resistant prostate cancer.
HER-2 Directed Therapies Making Waves in Early-Stage and Metastatic Breast Cancer
February 17, 2022
Article
A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.
Durvalumab Plus Tremelimumab Extends Overall Survival in Hepatocellular Carcinoma
January 20, 2022
Article
Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.
Targeted Therapy With Multigene Sequencing Shows Superior PFS Vs Chemotherapy in Metastatic Breast Cancer
December 08, 2021
Article
Patients who received matched targeted therapy specific to their genomic alteration, as identified through multigene sequencing, experienced significantly improved progression-free survival.
Third COVID-19 Vaccine Dose Effective and Safe in Patients with Lung Cancer
November 26, 2021
Article
A study in France showed that patients with lung cancer, a population initially excluded from COVID-19 vaccination registration trials, were able to safely receive 3 doses.